Advertisement

Medical Oncology

, Volume 27, Issue 2, pp 167–176 | Cite as

Treatment of NonHodgkin’s lymphomas with rituximab in Slovene patients

  • Barbara Jezeršek NovakovićEmail author
  • Ana Benigar
Original Paper

Abstract

The introduction of rituximab into the treatment of patients with NonHodgkin’s lymphomas has changed the long-term prognosis of patients with CD20 positive B cell lymphomas, especially follicular and diffuse large B-cell lymphomas (DLBCLs). The addition of rituximab to chemotherapy improves the overall response rate, prolongs the response duration and the overall survival both in patients with follicular and other indolent CD20 positive lymphomas, and DLBCLs. Maintenance treatment with rituximab in patients with indolent lymphomas further prolongs the remission duration, and some of the studies have also shown survival benefit. However, the maintenance therapy in aggressive lymphomas most probably gives no further improvement in patients, who have received rituximab already in the induction treatment. Rituximab has been used at the Institute of Oncology Ljubljana since 1998. In the period from 2004 to 2006, we have treated 340 patients with rituximab either as a single agent or in combination with chemotherapy. Our treatment group included 46.8% of patients with DLBCLs and 19.4% with follicular lymphomas. In majority of the patients, rituximab was given as the first-line treatment (54.4%), while 26.2% of patients received it as the second-line treatment and 19.4% of patients as the third or subsequent line of treatment. Among patients with indolent lymphomas, just 15% received rituximab as the first-line treatment. On the other hand, 75.9% of patients with aggressive lymphomas were treated with rituximab for newly diagnosed disease. About 67.4% of patients were treated with R–CHOP combination, while the others received different rituximab–chemotherapy combinations. The overall response rate regardless of the histological type of lymphoma was 78.8%, and the highest response rate was achieved in patients with aggressive follicular lymphomas (91.7%). The highest overall response rate was observed when rituximab was given as the first-line treatment in all lymphoma types except the mantle cell lymphoma (66.6% overall response rate for the first-line treatment versus 73.7% overall response rate for the second-line treatment). In 75% of patients regardless of the histological type of lymphoma, the response lasted more than 12 months; the median response duration has not been reached yet. In patients receiving rituximab as the first-line treatment, the median response duration also has not been reached yet, while for the second-line treatment, it was 25 months and for the third or subsequent line, 24 months. The longest disease-free survival was observed in patients with DLBCLs. The overall survival rate of all patients regardless of the type of lymphoma was 75% 26 months after the beginning of the treatment, and the median overall survival has not been reached yet. When analyzed by the lines of treatment—the median overall survival has not been reached in any line. The longest overall survival was observed in patients with indolent follicular lymphomas. The treatment results with rituximab at the Institute of Oncology Ljubljana are comparable to the results of larger randomized trials. According to the beneficial influence of rituximab on the long-term prognosis of patients with CD20 positive lymphomas, it became the standard of treatment in these patients.

Keywords

NonHodgkin’s lymphomas Treatment Rituximab 

References

  1. 1.
    Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. 2nd ed. Philadelphia: W.B. Saunders Company; 2006.Google Scholar
  2. 2.
    Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, et al., editors. Cancer incidence in Slovenia 2004. Ljubljana: Institute of Oncology, Cancer registry of Slovenia; 2007.Google Scholar
  3. 3.
    Molina A. A decade of rituximab: improving survival outcomes in Non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50. doi: 10.1146/annurev.med.59.060906.220345.CrossRefPubMedGoogle Scholar
  4. 4.
    Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of lymphoid malignancies. London: Martin Dunitz Ltd; 2001. p. 153–67.Google Scholar
  5. 5.
    Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121–43. doi: 10.1038/sj.onc.1208349.CrossRefPubMedGoogle Scholar
  6. 6.
    Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457–66.PubMedGoogle Scholar
  7. 7.
    Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann of Oncol. 2003;14:520–35. doi: 10.1093/annonc/mdg175.CrossRefGoogle Scholar
  8. 8.
    Maloney DG. Mechanisms of action of rituximab. Anticancer Drugs. 2001;12(Suppl 2):1–4. doi: 10.1097/00001813-200101000-00001.Google Scholar
  9. 9.
    Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Drugs. 2006;66:791–820. doi: 10.2165/00003495-200666060-00005.CrossRefPubMedGoogle Scholar
  10. 10.
    National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology-Version 1.2007. Non-Hodgkin’s lymphomas. http://www.nccn.org/professionals/physician.gls/PDF/nhl.pdf.
  11. 11.
    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23. doi: 10.1182/blood-2004-08-3175.CrossRefPubMedGoogle Scholar
  12. 12.
    Foussard C, Mounier N, Van Hoof A. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients. J Clin Oncol ASCO Annu Meet Proc. 2006;24:7508. (Abstr).Google Scholar
  13. 13.
    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group. Blood. 2005;106:3725–32. doi: 10.1182/blood-2005-01-0016.CrossRefPubMedGoogle Scholar
  14. 14.
    Herold M, Haas A, Srock S, Neser S, Al-Ali KH, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol. 2007;25:1986–92. doi: 10.1200/JCO.2006.06.4618.CrossRefPubMedGoogle Scholar
  15. 15.
    Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301. doi: 10.1182/blood-2006-05-021113.CrossRefPubMedGoogle Scholar
  16. 16.
    Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R–FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;108:4003–8. doi: 10.1182/blood-2006-04-016725.CrossRefPubMedGoogle Scholar
  17. 17.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, et al. Long-term results of the R–CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26. doi: 10.1200/JCO.2005.09.131.CrossRefPubMedGoogle Scholar
  18. 18.
    Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7. doi: 10.1200/JCO.2005.05.1003.CrossRefPubMedGoogle Scholar
  19. 19.
    Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7:379–91. doi: 10.1016/S1470-2045(06)70664-7.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  1. 1.Department of Medical OncologyInstitute of Oncology LjubljanaLjubljanaSlovenia
  2. 2.Faculty of PharmacyUniversity of LjubljanaLjubljanaSlovenia

Personalised recommendations